BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6134412)

  • 1. [Effects of Prenalterol on left ventricular function of coronary patients].
    Javernaro A; Bolognesi R; Giacometti P; Potenza D; Cortesi G; Cucchini F
    Acta Biomed Ateneo Parmense; 1983; 54(1):17-8. PubMed ID: 6134412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodynamic effects of prenalterol in patients with severe congestive heart failure--NYHA III-IV.
    Erbel R; Meyer J; Schweizer P; Lambertz H; Voelker W; Effert S
    Acta Med Scand Suppl; 1982; 659():169-80. PubMed ID: 6127887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of prenalterol on contractility, relaxation, and filling phase in coronary artery disease patients with previous myocardial infarction.
    Cucchini F; Baldi G; Bolognesi R; Ferrari R; Visioli O
    J Cardiovasc Pharmacol; 1984; 6(5):822-8. PubMed ID: 6209486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of beta-1-adrenergic agonists in the treatment of cardiac insufficiency].
    Coulombe D
    Ann Cardiol Angeiol (Paris); 1984; 33(4):207-10. PubMed ID: 6147113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.
    Tweddel AC; Murray RG; Pearson D; Martin W; Hutton I
    Br Heart J; 1982 Apr; 47(4):375-80. PubMed ID: 6121566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute effects of beta 1 agonism with prenalterol on catecholamine circulating levels in patients with congestive heart failure.
    Corea L; Bentivoglio M; Verdecchia P; Provvidenza M
    G Ital Cardiol; 1983 Nov; 13(11):330-4. PubMed ID: 6141975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro studies on the cardiac activity of prenalterol with reference to use in congestive heart failure.
    Kenakin TP; Beek D
    J Pharmacol Exp Ther; 1982 Jan; 220(1):77-85. PubMed ID: 6118432
    [No Abstract]   [Full Text] [Related]  

  • 8. Hemodynamic assessment of prenalterol: a cardioselective beta agonist in patients with imparied left ventricular function.
    Klein W; Brandt D; Maurer E
    Clin Cardiol; 1981; 4(6):325-9. PubMed ID: 6120057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemodynamic effects of prenalterol in patients with coronary heart disease.
    Hutton I; Murray RG; Boyes RN; Rae AP; Hillis WS
    Br Heart J; 1980 Feb; 43(2):134-7. PubMed ID: 6102468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardio-selective beta adrenergic stimulation with prenalterol in the conscious dog.
    Manders WT; Vatner SF; Braunwald E
    J Pharmacol Exp Ther; 1980 Oct; 215(1):266-70. PubMed ID: 6109017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of heart rate on the effects of prenalterol on regional myocardial blood flow and function during coronary stenosis in dogs.
    Berdeaux A; Bonhenry C; Duhazé P; Giudicelli JF; Thuillez C
    Br J Pharmacol; 1984 Sep; 83(1):203-10. PubMed ID: 6148979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic effects of atrial pacing and prenalterol infusion in patients taking beta-adrenergic blocking drugs.
    Shiu MF; Ireland MA; Littler WA
    Circulation; 1981 Dec; 64(6):1135-41. PubMed ID: 6117380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo.
    Glover DR; Wathen CG; Murray RG; Petch MC; Muir AL; Littler WA
    Br Heart J; 1985 Feb; 53(2):208-15. PubMed ID: 2857088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contractile, coronary, and metabolic effects of the acute and long-term treatment of cardiac failure with prenalterol.
    Strauer BE; Bohn I; Hahn B; Kment A; Motz U
    J Cardiovasc Pharmacol; 1984; 6(3):491-8. PubMed ID: 6202977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.
    Currie PJ; Kelly MJ; Middlebrook K; Federman J; Sainsbury E; Ashley J; Pitt A
    Br Heart J; 1984 May; 51(5):530-8. PubMed ID: 6326784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term effect of a new beta-agonist prenalterol in patients with severe congestive heart failure (author's transl)].
    Lambertz H; Erbel R; Meyer J; Schweizer P; Effert S
    Z Kardiol; 1982 Jan; 71(2):65-74. PubMed ID: 6122313
    [No Abstract]   [Full Text] [Related]  

  • 17. [New drugs with positive inotropic action].
    Bijak A; Czołpiński T
    Kardiol Pol; 1982; 25(4):357-65. PubMed ID: 6128439
    [No Abstract]   [Full Text] [Related]  

  • 18. Prenalterol in primary dilated cardiomyopathy: hemodynamic and angiographic evaluation.
    Branzi A; Specchia S; Binetti G; Magelli C; Zannoli R; Magnani B
    Eur Heart J; 1983 Apr; 4(4):252-8. PubMed ID: 6684041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prenalterol in the treatment of congestive heart failure developing during beta-blocking therapy. A comparison with frusemide in patients with acute myocardial infarction.
    Dahlström U; Karlsson E
    Acta Med Scand; 1982; 212(3):125-30. PubMed ID: 6128867
    [No Abstract]   [Full Text] [Related]  

  • 20. Haemodynamic effects of prenaterol and cardiac glycosides in patients with recent myocardial infarction.
    Boström PA; Andersson J; Johansson BW; Lilja B; Thorell J; Tidfält K; Westerling S
    Eur J Clin Invest; 1984 Jun; 14(3):175-80. PubMed ID: 6147253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.